Dr. Taler’s research established a new in-vivo model that enable fast and effective screening of potential secondary cataract preventing drugs. Kineret has wide experience working with in-vivo models, including mouse, rat and zebrafish.
Kineret earned a Ph.D. in Human Genetics at the Hebrew University of Jerusalem in the field of lens development and secondary cataract prevention.
